Published in Cancer Weekly, August 19th, 2003
The company incurred a net loss of $16.6 million, or $0.42 per share, basic and diluted. This is compared with a net loss in the second quarter of 2002 of $14.1 million, or $0.43 per share, basic and diluted. Research and development costs were $12 million in the second quarter of 2003, compared with $10 million for the same period in 2002.
The increased losses reflect the further progress of the company's clinical product candidates including Oncophage (HSPPC-96), Antigenics' lead product candidate in phase III development,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.